Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

BACKGROUND: Migraine is the second leading cause of disability worldwide. Although many preventive treatments reduce migraine frequency and severity, it is unclear whether these treatments reduce migraine-related disability in a clinically meaningful way. This pooled analysis evaluated the ability o...

Descripción completa

Detalles Bibliográficos
Autores principales: McAllister, Peter, Cohen, Joshua M., Campos, Verena Ramirez, Ning, Xiaoping, Janka, Lindsay, Barash, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422163/
https://www.ncbi.nlm.nih.gov/pubmed/36038833
http://dx.doi.org/10.1186/s10194-022-01438-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422163/
https://www.ncbi.nlm.nih.gov/pubmed/36038833
http://dx.doi.org/10.1186/s10194-022-01438-4

Ejemplares similares